Dedicated to
Assisting
Your Patients

With DARAPRIM Direct, your patients will have a dedicated DARAPRIM Case Manager to assist them through every step.

To learn how to prescribe DARAPRIM, click below.

Accessing DARAPRIM

Physicians' Office

Hospitals and 340B/PHS Facilities

Support

DARAPRIM Direct

The DARAPRIM Direct Program was created to help patients obtain quick and affordable access to DARAPRIM. From the moment you’ve prescribed DARAPRIM, dedicated Case Managers can help educate and support your patients through every step.

bulletlist bulletlist

Financial Assistance

The DARAPRIM Direct Program helps ensure that you have one less concern when it comes to getting your patients started on their medication. A DARAPRIM Case Manager will work with your patient to understand their insurance coverage, financial needs and the financial assistance programs that they may be eligible for.¹

¹Financial assistance programs are subject to terms and conditions and patient eligibility requirements. Restrictions, including where prohibited by law, may apply. Offers are subject to change or discontinuance without notice. Financial assistance programs are not insurance nor are they intended to be a substitute for insurance.

Forms & Resources

Find More Information

Important Safety Information

INDICATION

DARAPRIM® (pyrimethamine) is indicated for the:

  • Treatment of toxoplasmosis when used conjointly with a sulfonamide.
  • Treatment of acute malaria only in patients infected in areas where susceptible plasmodia exist and when used conjointly with a sulfonamide (e.g., sulfadoxine) to initiate transmission control and suppression of susceptible strains of plasmodia. It should NOT be used alone to treat acute malaria. Fast-acting schizonticides such as chloroquine or quinine are indicated and preferable for the treatment of acute malaria.
  • Chemoprophylaxis of malaria due to susceptible strains of plasmodia. It is not suitable as a prophylactic agent for travelers to most areas since resistance to pyrimethamine is prevalent worldwide.

IMPORTANT SAFETY INFORMATION

DARAPRIM is contraindicated in patients with known hypersensitivity to pyrimethamine or to any component of the formulation and in patients with documented megaloblastic anemia due to folate deficiency.

Potential for folate deficiency: Dosage required for toxoplasmosis treatment approaches the toxic level. If signs of folate deficiency develop, reduce the dosage or discontinue the drug according to patient response. Administer folinic acid (leucovorin) at 5-15 mg per day until normal hematopoiesis is restored.

Carcinogenic potential: Data indicates that pyrimethamine may be carcinogenic.

Adverse reactions:

  • Hypersensitivity reactions, occasionally severe (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and anaphylaxis), and hyperphenylalaninemia, can occur particularly when pyrimethamine is administered concomitantly with a sulfonamide. Consult the full prescribing information for relevant sulfonamide-associated adverse events.
  • Megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia, atrophic glossitis, hematuria, cardiac rhythm disorders, anorexia and vomiting may occur with doses used for toxoplasmosis treatment. Hematologic effects may also occur at low doses in certain individuals.
  • Pulmonary eosinophilia has been reported rarely.

Pregnancy Category C:

  • There are no adequate and well-controlled studies in pregnant women. DARAPRIM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should be warned against becoming pregnant during treatment with Daraprim.

Pyrimethamine is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from pyrimethamine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Keep out of the reach of infants and children: Deaths in pediatric patients have been reported after accidental ingestion.

Drug Interactions:

  • The concomitant use of pyrimethamine with other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim-sulfamethoxazole combination, proguanil , zidovudine, or cytostatic agents (e.g., methotrexate), may increase the risk of bone marrow suppression. If signs of folate deficiency develop, pyrimethamine should be discontinued and folinic acid should be given until hematopoiesis is restored (see above).
  • Use Daraprim with caution in patients receiving therapy, such as phenytoin, that affect folate levels.
  • Mild hepatotoxicity can occur when lorazepam and pyrimethamine are administered concomitantly.

Dosing Information:

  • For specific dosing instructions see the Full Prescribing Information.
  • Do not exceed the recommended dosage.
  • Start with a small dose for toxoplamosis in patients with convulsive disorders to avoid the potential nervous system toxicity of pyrimethamine (see Overdosage).
  • Use with caution in patients with impaired renal or hepatic function; in patients with possible folate deficiency such as individuals with malabsorption syndrome, alcoholism, or who are pregnant; and in the elderly due to the potential for decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this population.
  • Concurrent administration of folinic acid is strongly recommended when used for the treatment of toxoplasmosis in ALL patients.
  • In patients receiving a high dosage, as for the treatment of toxoplasmosis, semiweekly blood counts, including platelet counts should be performed.
  • Taking Daraprim with meals may minimize associated anorexia and vomiting.

Overdosage:

  • Following the ingestion of 300 mg or more of pyrimethamine, gastrointestinal and/or central nervous system signs may be present, including convulsions and death.
  • There is no specific antidote to acute pyrimethamine poisoning. Symptomatic and supportive measures should be employed. Gastric lavage is recommended and is effective if carried out very soon after drug ingestion. Parenteral diazepam may be used to control convulsions. Folinic acid should be administered within 2 hours of drug ingestion to be most effective in counteracting the effects on the hematopoietic system. Daily monitoring of peripheral blood counts is recommended for up to several weeks until normal hematologic values are restored.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. To report SUSPECTED ADVERSE REACTIONS contact Turing Pharmaceuticals LLC at 1-877-258-2033.

Please See Full Prescribing Information

DARAPRIM is a licensed trademark of Turing Pharmaceuticals AG.

Contact Us

For questions on how to access DARAPRIM, call 1-877-258-2033, press 2 or e-mail daraprim@turingpharma.com

To report an adverse event, product complaint or for medical information, call 1-877-258-2033, press 1 or e-mail usmedinfo@turingpharma.com